NEWS
OURPATH IS NOW SECOND NATURE
SEMAGLUTIDE
FOR T2S
CGM FOR BABY BUMPS
Due to feedback that OurPath sounded
like a cult and that the name also seemed
hard to say ('OurPlan, OnePath) and as
we all take a slightly different pathway
towards their goals, but all have habits
in common. Making healthy choices
second nature is the key to lasting lifestyle
changes. So OurPath has been renamed
Second Nature although nothing about the
programme, nutrition recommendations,
app features or any of the people at the
company have changed.
The programme was originally aimed
at people living with Type 2 diabetes and
those referred by GPs in the NHS but is
applicable to anybody looking to make
a lifestyle change, no matter what their
background or life situation who wants to
change their habits with regards to food.
OurPath was announced as one of
5 digital providers of the Healthier You:
NHS Diabetes Prevention Programme in
November 2017 with backing from Roche
Diabetes Care, a company whose strong
heritage has been built on pioneering
innovation over the past 40 years. Digital
therapeutics is part of a new phase of
healthcare revolution with both Roche
and the newly entitled Second Nature
having a shared ambition to empower
people to make sustainable changes
for the long-term. The partnership with
Roche Diabetes Care, saw the Second
Nature programme being offered to the
wider population at a much quicker pace.
Anybody who would like to invest in
building healthier habits for themselves is
able to sign up for the programme online
without having a GP referral.
Second Nature focuses on changing
everyday behaviours to support weight
management, including changes to
carbohydrate intake.
If you have any underlying conditions,
remember to discuss any new lifestyle
programme with your healthcare team
before starting as it may not be suitable
for every individual. It does not replace
any medical advice you already received
relating to diet and lifestyle.
www.secondnature.io
Dexcom G6 CGM system has received
the CE Mark for use during pregnancy in
the EU, and will be available soon, starting
with the UK in spring 2020.
Poorly controlled glucose levels in
pregnant women with Type 1, Type 2 or
gestational diabetes can lead to serious
problems for the mother and child, and
the solutions for managing diabetes
during pregnancy are currently limited. The
CE Mark of the Dexcom G6 for pregnant
women provides more choice for both
healthcare professionals and patients to
manage their disease.
Helen Murphy, MD, professor of
medicine at the University of East Anglia in
Norwich, U.K. "CGM eliminates
the need for fingersticks and provides
patients with regular updates and alerts
throughout the day and night. This allows
them to manage their glucose levels with
confidence during pregnancy and helps
them to deliver healthy babies."
www.dexcom.com
The European Medicines Agency's
human medicines committee (CHMP)
has recommended granting a marketing
authorization in the EU for Rybelsus
(semaglutide) for the treatment of adults
with insufficiently controlled Type 2
diabetes to improve glycaemic control
as an adjunct to diet and exercise. It is
the first glucagon-like peptide (GLP-1)
receptor agonist treatment (a class of
non-insulin medicines for people with
type 2 diabetes) developed for oral use,
providing patients with another option
to treat the disease without injections.
The opinion adopted by the CHMP is an
intermediary step on Rybelsus's path to
patient access.